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Background: Multiple endocrine neoplasia type 1 (MEN1) is a familial syndrome characterized by the parathyroid, pancreas and 
pituitary tumors. Parathyroid tumors are the most common clinical manifestations, occurring in more than 90% of MEN1 pa-
tients. Heterozygous germline mutations of the MENIN gene underlie the tumorigenesis in MEN1 and epigenetic alterations 
along with germline mutations may contribute to tumorigenesis. Here, we investigated the associations between genotype and 
phenotype in Korean MEN1 patients.  
Methods: We analyzed medical records from 14 unrelated MEN1 patients who had newly confirmed MENIN germline muta-
tions, together with 14 previous reports in Korea. Aberrant DNA methylations were also examined in MEN1-related parathyroid 
tumors using the Infinium HumanMethylation 450 BeadChip. 
Results: Total 28 germline mutations of MENIN were relatively highly concentrated in exons 7 and 8 compared to previous re-
ports from Western countries. Six mutations (c.111dupT/p.S38Ffs*79, c.225_226insT/p.T76Yfs*41, c.383_398del16/p.S128T-
fs*52, c.746dupT/p.H250Afs*20, c.1150G>T/p.E384*, and c.1508G>A/p.G503N) were newly found in the present study. Of 
interest, four patients (15%) showed unusual initial presentations and three patients were diagnosed incidentally at the general 
medical checkup. We also found three distinct sites in exon 2 of MENIN were significantly hypomethylated in the MEN1 para-
thyroid tumors, comparing correspondent blood samples. 
Conclusion: We also have found a lack of genotype/phenotype correlation in Korean MEN1 patients. There were not a few un-
usual initial manifestations in MEN1 patients, thus, genetic testing for the MENIN germline mutations can provide important in-
formation for the better prognosis. Further studies are warranted to investigate altered DNA methylations in the MENIN gene in-
volved in tumorigenesis.
Keywords: Germ-line mutation; DNA methylation; Multiple endocrine neoplasia type 1; Korea
INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal 
dominant hereditary disorder characterized by the combined 
occurrence of tumors of the parathyroid glands, pancreas and 
anterior pituitary gland [1-3]. In addition to these major le-
sions, adrenal gland tumors, facial angiofibroma, collageno-
ma, ependymoma, and thyroid lesions are also observed [2,3]. 
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The prevalence of hyperparathyroidism is more than 90% in 
MEN1 patients and that of pancreas tumors and pituitary tu-
mors are 40% to 70% and 30% to 60%, respectively [3]. In 
Korean literature, since the first case of MEN1, diagnosed ra-
diologically, was reported in 1986 [4], a total of 46 cases have 
been reported including the present study. Among total cases, 
28 unrelated patients were confirmed by the germline muta-
tions of the MENIN gene, but there is a scarcity of data delin-
eating genotype-phenotype relationships in Korean patients.
 MEN1 is caused by germline mutations of the MENIN tu-
mor suppressor gene linked to the chromosomal locus 11q13 
[5,6]. The gene consists of one untranslated and nine coding 
exons, encoding the 610 amino acid protein, menin [5]. More 
than 400 germline and somatic mutations in MENIN have 
been found throughout the whole coding sequences, and most 
of the mutations predict a premature protein truncation [2,5]. 
However, the absence of a mutational ‘hot spot’ and lack of 
genotype-phenotype correlations in MEN1 have been estab-
lished so far [2,7,8]. This challenging finding might have been 
affected by additional genetic or epigenetic changes involved 
in tumorigenesis.
 Growing evidence shows that abnormal DNA methylation, 
along with genetic alterations lead to altered patterns of gene 
expression in tumorigenesis [9]. DNA methylation plays an 
important role in silencing tissue-specific genes, imprinted 
genes, and repetitive elements [10]. Recently, comprehensive 
analysis of DNA methylation alterations in benign and malig-
nant parathyroid tumors has been reported [9]. However, little 
is known about tissue specific methylation, especially regard-
ing the MENIN gene in parathyroid tumors due to germline 
mutation of MENIN.
 Therefore, we investigated the results of extensive genetic 
analysis of MENIN together with clinical phenotypes, and ana-
lyzed genotype/phenotype correlations in Korean MEN1 pa-
tients. Furthermore, we examined DNA methylation status in 
MEN1-related parathyroid tumors and compared those to pat-
terns observed in corresponding peripheral blood. 
METHODS
Patients 
We first reviewed the medical records of 14 unrelated MEN1 
patients who had germline mutations of the MENIN gene con-
firmed in Severance Hospital (Seoul, Korea). We evaluated the 
extended data from a total of 28 unrelated patients including 
14 cases in the present study and 14 cases previously reported 
with genetic confirmation in Korea by searching on PubMed 
and KoreaMed [11-21]. The clinical characteristics of six fam-
ily members were collected for MENIN germline mutation 
carriers to analyze any relationship between genotypes and 
phenotypes. The diagnosis of MEN1 was based on the pres-
ence of at least two of three main MEN1-related endocrine tu-
mors (parathyroid, pituitary, and pancreas neuroendocrine tu-
mors). Familial MEN1 was defined as one MEN1 case and at 
least one first-degree relative with at least one of the three 
main MEN1-related tumors, as previously established [22]. 
Approval was obtained from the Institutional Review Board of 
Severance Hospital, Yonsei University College of Medicine in 
2011 (4-2011-0613).
Germline mutation analysis of the MENIN gene
Genomic DNA was isolated from peripheral blood leukocytes 
using a QIAamp DNA Blood Mini Kit (QIAGEN GmbH, 
Hilden, Germany) according to the manufacturer’s instructions. 
The nine exons of the MENIN gene as well as their flanking in-
trons were amplified using primers. Polymerase chain reaction 
(PCR) was carried out using a thermal cycler (model 9700, Ap-
plied Biosystems, Foster City, CA, USA) as follows: 35 cycles 
of denaturation at 94°C for 30 seconds, annealing at 60°C for 
30 seconds, and extension at 72°C for 1 minute. The amplicon 
was purified using Agencourt AMPure XP (Beckman Coulter 
Genomics, Danvers, MA, USA). Direct sequencing was per-
formed using the BigDye Terminator Cycle Sequencing Ready 
Reaction kit on an ABI Prism 3130 genetic analyzer. All vari-
ants were confirmed based on the NCBI Single Nucleotide 
Polymorphism database (http://www.ncbi.nlm.nih.gov/SNP) 
and Human Gene Mutation Database database (http://www.
hgmd.org).
DNA methylation profiling
We used MEN1-related parathyroid tumors to investigate 
DNA methylation profiling because we could only get the tu-
mor tissues after parathyroidectomy. Six MEN1-related para-
thyroid tumors from the patients in Table 1 (cases 2-1, 8, 12, 
19, 25, and 26) and five of their blood samples (cases 1, 2-1, 8, 
12, and 25) were obtained, and consent was obtained from all 
participants in this study. The sodium bisulfite conversion was 
performed on 1 mg of genomic DNA for each sample with the 
EZ DNA kit (Zymo Research, Orange, CA, USA), and 200 ng 
of the converted DNA was used for PCR amplification. Am-
plified DNA was hybridized on the Infinium HumanMethyl-
ation 450 BeadChip (Illumina, San Diego, CA, USA) follow-
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ing the standard protocols. The hybridized images were pro-
cessed and intensity data was then extracted after scanning us-
ing an Illumina HiScan SQ scanner. β Values ranging from 0 
to 1 were calculated for the DNA methylation profile of each 
candidate. Finally, the candidates were ranked and selected 
base on the delta-beta (difference between β values) using the 
Illumina’s GenomeStudio Methylation Module, as previously 
reported [23].
RESULTS
Germline mutations of the MENIN gene in Korea
In the present study, we identified 14 germline mutations of the 
MENIN gene in seven familial and seven sporadic MEN1 pa-
tients by direct sequencing. Herein, we extensively collected 
germline mutations of the MENIN gene in Korean MEN1 pa-
tients from previous reports. There were 28 germline mutations 
in total 34 members of 14 familial (50%) and 14 sporadic cases 
(50%) (Table 1), and the distribution is shown in Fig. 1. Major-
ity of the mutations were concentrated in exon 2 (11/28, 39%), 
9 (4/28, 14%), and exon 10 (3/28, 11%) which are nine known 
sites of higher frequency previously classified as I to IX, but 
unexpected higher frequency in the excluded sites of exons 7 
and 8 (14%) were also found in our cases (Fig. 1) [3]. Most of 
the mutations resulted in frameshift changes which were found 
in 14 unrelated patients (50%), and five nonsense mutations 
(18%), eight missense mutations (29%), and one splice site 
mutation (3%) were documented (Fig. 2). In-frame deletion/
insertion mutation or large deletion was not found in this study. 
Six mutations (c.111dupT/p.S38Ffs*79, c.225_226insT/p.
T76Yfs*41, c.383_398del16/p.S128Tfs*52, c.746dupT/p.
H250Afs*20, c.1150G>T/p.E384*, and c.1508G>A/p.G503N) 
were newly confirmed as novel in the present study and the 
four (c.969C>A/p.Y323*, c.973G>C/p.A325P, c.1213C>T/
p.Q405*, and c.1049A>T/p.D350V) have been previously de-
scribed as novel in Korea (Table 1, Fig. 1). 
Clinical phenotypes of MEN1 in Korea
The phenotypic expression of MEN1 in all 34 cases is summa-
rized in Table 1. The most common manifestations were para-
thyroid tumors (94%, 32/34), pancreas tumors (88%, 30/34), 
and pituitary tumors (68%, 23/34). Less common MEN1-relat-
ed tumors were documented in 62% of the patients (21/34): 
seven adrenal adenomas, six carcinoid tumors (in the stomach, 
thymus, liver, and lung), two lipomas, and two spinal cord tu-
mors (ependymoma and schwannoma). Finally, 21 patients T
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(62%) had combined tumor involvement of all three main tar-
get endocrine glands; 26% (9/34) presented with tumors of the 
two glands; and 12% (4/34) with one gland.
 The first clinical manifestations were available in 30 cases 
and their mean age was 45 years (median age, 46; range, 21 to 
81) (Fig. 3). Three of them (cases 3, 6, and 23 in Table 1) were 
asymptomatic and incidentally diagnosed at a general health 
checkup. Two of these cases (cases 3 and 6) had incidentally 
detected concurrent pancreas and adrenal tumors at the medi-
cal checkup. Among 27 symptomatic patients, hyperparathy-
roidism or hypercalcemia were the first clinical manifestations 
of MEN1 in 10 patients (median age, 46 years; range 29 to 81 
Fig. 1. Summary data of germline mutations of MENIN in 28 unrelated patients with multiple endocrine neoplasia type 1 in Korea. The 
positions of the mutations in MENIN are illustrated above respective exons. ATG refers to the start codon; TGA refers to the stop codon. 
aMutations were reported as novel in Korea including the present study. Germline mutations (I to IX) that occur with a frequency >1.5% 
are shown and their respective frequencies (scale shown on the right lower) in the review are indicated by the vertical lines at lower part 
of the gene [3]. These germline mutations, which collectively represent 20.6% of all reported germline mutations, are: I, c.249_252del 
GTCT (4.5%); II, c.292C>T (1.5%); III, c.358_360delAAG (1.7%); IV, c.628_631delACAG (2.5%); V, c.784-9G>A (1.9%); VI, c.1243C 
>T (1.5%); VII, c.1378C>T (2.6%); VIII, c.1546delC (1.8%); IX, c.1546_1547insC (2.7%).
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Fig. 3. First manifestations of multiple endocrine neoplasia type 1 
(MEN1) in Korea. Among 27 symptomatic patients, hyperpara-
thyroidism was documented in 10 patients (37%), pancreas tu-
mors in 10 (37%), and pituitary tumors in three (11%). Four pa-
tients (15%) showed less common tumors associated with MEN1 
as a first manifestation.
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Fig. 2. Frequencies of the types of MENIN mutations detected in 
28 unrelated patients with multiple endocrine neoplasia type 1. In-
frame deletion/insertion was not detected. Gross deletion was not 
confirmed. 
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years), pancreas tumors in 10 (median age, 36 years; range 21 
to 70 years), and pituitary tumors in three patients (median 
age, 26 years; range 24 to 34 years) (Fig. 3). Four patients 
(median age, 44 years; range 27 to 57 years) showed less com-
mon tumors associated with MEN1 as a first manifestation, 
including carcinoid tumors in the stomach or lung and the ad-
renal cortical adenoma associated with Cushing syndrome 
(Fig. 3).
 Defining the relationship between the germline mutations 
of MENIN and the associated with clinical manifestations of 
MEN1, we could not find any direct genotype-phenotype cor-
relations in this study, as already shown by other studies. 
Fig. 4. Distinct methylation pattern of hereditary parathyroid tumors compared to respective blood controls (A) and methylation profile 
of the MENIN gene (B). (A) Heatmap of all differentially methylated genes showing distinct methylation patterns of multiple endocrine 
neoplasia type 1 (MEN1)-related parathyroid tumors. Heatmap color corresponds to the β-value of the measured CpG-sites. β Ranges 
from 0 (purely unmethylated, shown in pink) to 1 (purely methylated, shown in green). (B) In this line plot blood average β is indicated 
by a black line and the parathyroid tissue average β is indicated by a grey line. Significant methylation differences are confined to exon 2 
of the MENIN gene: three hypomethylation sites (cg10879244, cg22897141, and cg22527280) are described in the grey box with black 
arrows. The samples for heatmap are indicated according to specimen (B=blood sample and P=parathyroid tumor); digits after the hy-
phen denote case numbers as shown in Table 1. DMR, differentially methylated regions.
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DNA methylation profiling in parathyroid tumors
We examined DNA methylation status in MEN1-related para-
thyroid tumors comparing to those corresponding to the pat-
terns observed in peripheral blood using the Infinium Human-
Methylation 450 BeadChip. Distinct hierarchical clustering of 
genes with altered DNA methylation profiles in blood controls 
and MEN1 parathyroid tumors was evident (Fig. 4A). The 5’ 
region of MENIN contains a high proportion of “CpG islands.” 
Among these dinucleotides, three sites were significantly hypo-
methylated in the exon 2 of MENIN: chr11, position 64,577,190 
(cg10879244, β=–0.329, P<0.001), 64,577,338 (cg22897141, 
β=–0.163, P=0.001), and 64,577,427 (cg22527280, β=–0.063, 
P<0.001) (Fig. 4B). 
DISCUSSION
The screening for germline mutations of the MENIN gene 
makes it possible to perform early diagnosis and better clinical 
management for mutation carriers. Unfortunately, few studies 
to date have done genetic testing for MEN1 in Korea; a total 
of 28 germline mutations (14 familial and 14 sporadic muta-
tions) have been characterized in Korean MEN1 patients. The 
majority (71%) of the mutations were inactivating ones that 
would result from the frameshift, nonsenses, and splice site 
mutations that are consistent with previous reports [2,24,25]. 
We could not find in-frame deletion/insertion mutations in this 
work, indicating low frequency of this mutation in Korean 
MEN1; similar to findings in other populations [2]. 
 Parathyroid tumors are often the first manifestation of MEN1 
in more than 85% of patients [26,27]. Meanwhile, hyperpara-
thyroidism by the parathyroid tumor, and pancreas tumors were 
less common presentations in this study; each appearing in 
37% of the patients. On the other hand, 15% of the patients 
showed unusual initial manifestation of MEN1 (Fig. 3). We 
identified one case (case 8 in Table 1) with Cushing syndrome 
due to adrenal cortical adenoma as a first presentation of the 
disorder. The patient also had spinal cord ependymoma which 
less commonly develops in MEN1 patients. The prevalence of 
adrenal lesions in patients with MEN1 varies from 36% to 73% 
and most of them are nonfunctional [28,29]. Cushing syndrome 
due to adrenal cortical adenomas as a MEN1-related lesion is 
very rare, and has been documented in only three cases report-
ed worldwide including this case [30,31]. The other two cases 
had nonsense mutations (c.781C>T) in the exon 4 [30] or 
splicing mutation (c.912+1G>A, IVS6+1G>A) in the intron 6 
[31]. These mutations would lead to a disruption and loss of 
function of MENIN.
 Four cases (4/35, 11%) had been diagnosed with papillary 
thyroid cancer concurrently with MEN1-related tumors. Thy-
roid disease is known to be detected incidentally in over 25% 
of MEN1 patients [32,33]. Normal thyroid glands have been 
shown to express menin [34], thus, thyroid tumors in MEN1 
patients possibly involved with the MENIN mutations. Genetic 
analysis of less common tumors such as carcinoids, lipomas, 
angiofibromas, and esophageal and uterine leiomyomas have 
reported a loss of heterozygosity (LOH), indicating a role for 
MENIN mutation in the etiology of these tumors as predicted 
by the two-hit model of Knudson [35,36]. But no evidence of 
LOH in the papillary thyroid cancer in MEN1 was reported in 
two cases [32,36]; thus, it seems that loss of the tumor sup-
pressor function of menin is not required for the tumor forma-
tion in these cases. However, in this study, papillary thyroid 
cancer was the most common manifestation together with ad-
renal adenoma next to the main three lesions in MEN1 pa-
tients. Thus, other genetic alterations without obvious LOH of 
the gene locus should have occurred.
 As we expected, correlations between MENIN mutations and 
clinical manifestations also appear to be absent in this study. 
Regarding the two frameshift mutations, c.196_200dupAGCCC 
and c.200_201insAGCCC (exon 2), each occurred three times, 
and one, c.628_631delACAG, occurred twice in the different 
unrelated patients. Even in the patients with same mutations and 
individual members of the same family, a wide range of MEN1-
associated tumors and a lack of genotype/phenotype correla-
tions were revealed. This finding may suggest various clinical 
manifestations may be caused by tissue-specific modulations 
such as epigenetic factors. Therefore, we attempted to find epi-
genetic changes using a methylation study in MEN1-related 
parathyroid tumors. 
 In the context of the Knudson two-hit hypothesis, up to 80% 
of MEN1-associated tumors exhibited LOH of 11q13 [37]. 
Even though the LOH of parathyroid tumors was not con-
firmed in this study, we attempted to determine DNA methyla-
tion profiles in MEN1-related parathyroid tumors and compare 
these to respective blood samples. There was altered DNA 
methylation in the MENIN gene of MEN1-related parathyroid 
tumors. DNA methylation of the first exon is associated with 
tissue-specific regulation of gene expression [38]. Although 
we were not able to determine the role of the three hypometh-
ylations in the MENIN gene identified in this study, these 
modifications possibly play a role in the parathyroid tumori-
genesis and future studies are warranted.
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 To summarize the status of Korean MEN1: (1) there were 
relatively high frequency of the mutations in exons 7 and 8 of 
the MENIN gene; (2) unusual initial manifestations of MEN1 
were present in a quite a few MEN1 patients in Korea; thus, 
genetic testing can provide important information for clearer 
diagnosis; and (3) the analysis for epigenetic factors regarding 
tumorigenesis should be considered more carefully. 
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